nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Ocular discomfort—Methotrexate—esophageal cancer	0.0426	0.0426	CcSEcCtD
Apraclonidine—Scab—Capecitabine—esophageal cancer	0.0408	0.0409	CcSEcCtD
Apraclonidine—Visual acuity reduced—Capecitabine—esophageal cancer	0.0218	0.0219	CcSEcCtD
Apraclonidine—Rhinorrhoea—Cisplatin—esophageal cancer	0.0217	0.0218	CcSEcCtD
Apraclonidine—Infection—Carboplatin—esophageal cancer	0.0213	0.0213	CcSEcCtD
Apraclonidine—Keratitis—Capecitabine—esophageal cancer	0.02	0.02	CcSEcCtD
Apraclonidine—Pain—Carboplatin—esophageal cancer	0.0183	0.0183	CcSEcCtD
Apraclonidine—Rhinorrhoea—Capecitabine—esophageal cancer	0.016	0.016	CcSEcCtD
Apraclonidine—Eye irritation—Capecitabine—esophageal cancer	0.0152	0.0152	CcSEcCtD
Apraclonidine—Lacrimation increased—Capecitabine—esophageal cancer	0.0141	0.0141	CcSEcCtD
Apraclonidine—Inflammation—Capecitabine—esophageal cancer	0.0134	0.0134	CcSEcCtD
Apraclonidine—Coordination abnormal—Capecitabine—esophageal cancer	0.0132	0.0132	CcSEcCtD
Apraclonidine—Face oedema—Cisplatin—esophageal cancer	0.0123	0.0124	CcSEcCtD
Apraclonidine—Irritability—Cisplatin—esophageal cancer	0.0122	0.0122	CcSEcCtD
Apraclonidine—Dry eye—Capecitabine—esophageal cancer	0.012	0.012	CcSEcCtD
Apraclonidine—Nasopharyngitis—Cisplatin—esophageal cancer	0.0114	0.0114	CcSEcCtD
Apraclonidine—Abnormal vision—Capecitabine—esophageal cancer	0.0113	0.0113	CcSEcCtD
Apraclonidine—Abdominal discomfort—Cisplatin—esophageal cancer	0.0106	0.0106	CcSEcCtD
Apraclonidine—Eye pain—Capecitabine—esophageal cancer	0.0104	0.0105	CcSEcCtD
Apraclonidine—Libido decreased—Capecitabine—esophageal cancer	0.0102	0.0102	CcSEcCtD
Apraclonidine—Inflammation—Methotrexate—esophageal cancer	0.00997	0.00997	CcSEcCtD
Apraclonidine—Conjunctivitis—Cisplatin—esophageal cancer	0.00958	0.00959	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00935	0.00936	CcSEcCtD
Apraclonidine—Face oedema—Capecitabine—esophageal cancer	0.0091	0.00911	CcSEcCtD
Apraclonidine—Bradycardia—Cisplatin—esophageal cancer	0.00901	0.00901	CcSEcCtD
Apraclonidine—Irritability—Capecitabine—esophageal cancer	0.009	0.009	CcSEcCtD
Apraclonidine—Visual impairment—Cisplatin—esophageal cancer	0.00852	0.00853	CcSEcCtD
Apraclonidine—Nasopharyngitis—Capecitabine—esophageal cancer	0.00843	0.00844	CcSEcCtD
Apraclonidine—Eye disorder—Cisplatin—esophageal cancer	0.00827	0.00827	CcSEcCtD
Apraclonidine—Asthma—Capecitabine—esophageal cancer	0.00815	0.00815	CcSEcCtD
Apraclonidine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00797	0.00798	CcSEcCtD
Apraclonidine—Arrhythmia—Cisplatin—esophageal cancer	0.0079	0.00791	CcSEcCtD
Apraclonidine—Abdominal discomfort—Capecitabine—esophageal cancer	0.00781	0.00782	CcSEcCtD
Apraclonidine—Erythema—Cisplatin—esophageal cancer	0.0077	0.00771	CcSEcCtD
Apraclonidine—Infestation—Capecitabine—esophageal cancer	0.00726	0.00727	CcSEcCtD
Apraclonidine—Infestation NOS—Capecitabine—esophageal cancer	0.00726	0.00727	CcSEcCtD
Apraclonidine—Vision blurred—Cisplatin—esophageal cancer	0.00726	0.00726	CcSEcCtD
Apraclonidine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00714	0.00715	CcSEcCtD
Apraclonidine—Conjunctivitis—Capecitabine—esophageal cancer	0.00706	0.00707	CcSEcCtD
Apraclonidine—Malaise—Cisplatin—esophageal cancer	0.00694	0.00695	CcSEcCtD
Apraclonidine—Irritability—Methotrexate—esophageal cancer	0.0067	0.0067	CcSEcCtD
Apraclonidine—Bradycardia—Capecitabine—esophageal cancer	0.00664	0.00664	CcSEcCtD
Apraclonidine—Myalgia—Cisplatin—esophageal cancer	0.00656	0.00656	CcSEcCtD
Apraclonidine—Rhinitis—Capecitabine—esophageal cancer	0.00654	0.00654	CcSEcCtD
Apraclonidine—Haemorrhage—Capecitabine—esophageal cancer	0.00652	0.00653	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00651	0.00652	CcSEcCtD
Apraclonidine—Discomfort—Cisplatin—esophageal cancer	0.00648	0.00648	CcSEcCtD
Apraclonidine—Pharyngitis—Capecitabine—esophageal cancer	0.00647	0.00648	CcSEcCtD
Apraclonidine—Oedema peripheral—Capecitabine—esophageal cancer	0.00642	0.00643	CcSEcCtD
Apraclonidine—Oedema—Cisplatin—esophageal cancer	0.00628	0.00629	CcSEcCtD
Apraclonidine—Visual impairment—Capecitabine—esophageal cancer	0.00628	0.00629	CcSEcCtD
Apraclonidine—Infection—Cisplatin—esophageal cancer	0.00624	0.00625	CcSEcCtD
Apraclonidine—Nervous system disorder—Cisplatin—esophageal cancer	0.00616	0.00617	CcSEcCtD
Apraclonidine—Skin disorder—Cisplatin—esophageal cancer	0.0061	0.00611	CcSEcCtD
Apraclonidine—Eye disorder—Capecitabine—esophageal cancer	0.00609	0.0061	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—esophageal cancer	0.00606	0.00607	CcSEcCtD
Apraclonidine—Angiopathy—Capecitabine—esophageal cancer	0.00592	0.00592	CcSEcCtD
Apraclonidine—Mediastinal disorder—Capecitabine—esophageal cancer	0.00588	0.00588	CcSEcCtD
Apraclonidine—Arrhythmia—Capecitabine—esophageal cancer	0.00583	0.00583	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00581	0.00582	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00573	0.00573	CcSEcCtD
Apraclonidine—Mental disorder—Capecitabine—esophageal cancer	0.00571	0.00572	CcSEcCtD
Apraclonidine—Erythema—Capecitabine—esophageal cancer	0.00568	0.00568	CcSEcCtD
Apraclonidine—Paraesthesia—Cisplatin—esophageal cancer	0.00564	0.00565	CcSEcCtD
Apraclonidine—Dyspnoea—Cisplatin—esophageal cancer	0.0056	0.00561	CcSEcCtD
Apraclonidine—Dysgeusia—Capecitabine—esophageal cancer	0.00556	0.00556	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00543	0.00543	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—esophageal cancer	0.00541	0.00541	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—esophageal cancer	0.00541	0.00541	CcSEcCtD
Apraclonidine—Pain—Cisplatin—esophageal cancer	0.00537	0.00538	CcSEcCtD
Apraclonidine—Vision blurred—Capecitabine—esophageal cancer	0.00535	0.00535	CcSEcCtD
Apraclonidine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00527	0.00527	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—esophageal cancer	0.00526	0.00526	CcSEcCtD
Apraclonidine—Feeling abnormal—Cisplatin—esophageal cancer	0.00518	0.00518	CcSEcCtD
Apraclonidine—Malaise—Capecitabine—esophageal cancer	0.00512	0.00512	CcSEcCtD
Apraclonidine—Syncope—Capecitabine—esophageal cancer	0.00509	0.0051	CcSEcCtD
Apraclonidine—Palpitations—Capecitabine—esophageal cancer	0.00502	0.00502	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—esophageal cancer	0.00485	0.00486	CcSEcCtD
Apraclonidine—Myalgia—Capecitabine—esophageal cancer	0.00483	0.00484	CcSEcCtD
Apraclonidine—Chest pain—Capecitabine—esophageal cancer	0.00483	0.00484	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—esophageal cancer	0.00482	0.00482	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.0048	0.0048	CcSEcCtD
Apraclonidine—Discomfort—Capecitabine—esophageal cancer	0.00477	0.00478	CcSEcCtD
Apraclonidine—Dry mouth—Capecitabine—esophageal cancer	0.00473	0.00473	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—esophageal cancer	0.00468	0.00468	CcSEcCtD
Apraclonidine—Oedema—Capecitabine—esophageal cancer	0.00463	0.00464	CcSEcCtD
Apraclonidine—Hypersensitivity—Cisplatin—esophageal cancer	0.00463	0.00463	CcSEcCtD
Apraclonidine—Infection—Capecitabine—esophageal cancer	0.0046	0.00461	CcSEcCtD
Apraclonidine—Nervous system disorder—Capecitabine—esophageal cancer	0.00454	0.00455	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—esophageal cancer	0.00454	0.00454	CcSEcCtD
Apraclonidine—Asthenia—Cisplatin—esophageal cancer	0.00451	0.00451	CcSEcCtD
Apraclonidine—Skin disorder—Capecitabine—esophageal cancer	0.0045	0.0045	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—esophageal cancer	0.0044	0.00441	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00437	0.00438	CcSEcCtD
Apraclonidine—Diarrhoea—Cisplatin—esophageal cancer	0.0043	0.0043	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—esophageal cancer	0.00425	0.00426	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—esophageal cancer	0.00423	0.00423	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00422	0.00422	CcSEcCtD
Apraclonidine—Insomnia—Capecitabine—esophageal cancer	0.00419	0.00419	CcSEcCtD
Apraclonidine—Paraesthesia—Capecitabine—esophageal cancer	0.00416	0.00416	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—esophageal cancer	0.00414	0.00414	CcSEcCtD
Apraclonidine—Dyspnoea—Capecitabine—esophageal cancer	0.00413	0.00413	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.004	0.004	CcSEcCtD
Apraclonidine—Vomiting—Cisplatin—esophageal cancer	0.004	0.004	CcSEcCtD
Apraclonidine—Fatigue—Capecitabine—esophageal cancer	0.00399	0.004	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—esophageal cancer	0.00398	0.00399	CcSEcCtD
Apraclonidine—Pain—Capecitabine—esophageal cancer	0.00396	0.00397	CcSEcCtD
Apraclonidine—Constipation—Capecitabine—esophageal cancer	0.00396	0.00397	CcSEcCtD
Apraclonidine—Dermatitis—Cisplatin—esophageal cancer	0.00396	0.00396	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—esophageal cancer	0.00392	0.00392	CcSEcCtD
Apraclonidine—Feeling abnormal—Capecitabine—esophageal cancer	0.00382	0.00382	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—esophageal cancer	0.00381	0.00381	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00379	0.00379	CcSEcCtD
Apraclonidine—Nausea—Cisplatin—esophageal cancer	0.00373	0.00374	CcSEcCtD
Apraclonidine—Abdominal pain—Capecitabine—esophageal cancer	0.00366	0.00367	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—esophageal cancer	0.0036	0.0036	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—esophageal cancer	0.0036	0.0036	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00357	0.00358	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—esophageal cancer	0.00355	0.00356	CcSEcCtD
Apraclonidine—Infection—Methotrexate—esophageal cancer	0.00343	0.00343	CcSEcCtD
Apraclonidine—Hypersensitivity—Capecitabine—esophageal cancer	0.00341	0.00342	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—esophageal cancer	0.00338	0.00339	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—esophageal cancer	0.00335	0.00335	CcSEcCtD
Apraclonidine—Asthenia—Capecitabine—esophageal cancer	0.00332	0.00333	CcSEcCtD
Apraclonidine—Pruritus—Capecitabine—esophageal cancer	0.00328	0.00328	CcSEcCtD
Apraclonidine—Diarrhoea—Capecitabine—esophageal cancer	0.00317	0.00317	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00314	0.00314	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—esophageal cancer	0.00312	0.00312	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—esophageal cancer	0.0031	0.0031	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—esophageal cancer	0.00307	0.00308	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—esophageal cancer	0.00307	0.00307	CcSEcCtD
Apraclonidine—Dizziness—Capecitabine—esophageal cancer	0.00306	0.00307	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00298	0.00298	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—esophageal cancer	0.00297	0.00298	CcSEcCtD
Apraclonidine—Pain—Methotrexate—esophageal cancer	0.00295	0.00295	CcSEcCtD
Apraclonidine—Vomiting—Capecitabine—esophageal cancer	0.00295	0.00295	CcSEcCtD
Apraclonidine—Dermatitis—Capecitabine—esophageal cancer	0.00292	0.00292	CcSEcCtD
Apraclonidine—Headache—Capecitabine—esophageal cancer	0.0029	0.0029	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—esophageal cancer	0.00284	0.00284	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00282	0.00282	CcSEcCtD
Apraclonidine—Nausea—Capecitabine—esophageal cancer	0.00275	0.00275	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—esophageal cancer	0.00273	0.00273	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—esophageal cancer	0.00254	0.00254	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—esophageal cancer	0.00247	0.00248	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—esophageal cancer	0.00244	0.00244	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—esophageal cancer	0.00236	0.00236	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—esophageal cancer	0.00228	0.00228	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—esophageal cancer	0.00219	0.00219	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—esophageal cancer	0.00217	0.00217	CcSEcCtD
Apraclonidine—Headache—Methotrexate—esophageal cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—esophageal cancer	0.00205	0.00205	CcSEcCtD
Apraclonidine—ADRA2A—Metabolism—PLCE1—esophageal cancer	1.49e-06	0.00155	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ADH7—esophageal cancer	1.49e-06	0.00155	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADCYAP1—esophageal cancer	1.47e-06	0.00153	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GHRL—esophageal cancer	1.46e-06	0.00153	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ABL1—esophageal cancer	1.46e-06	0.00152	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PDE4D—esophageal cancer	1.46e-06	0.00152	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—SST—esophageal cancer	1.46e-06	0.00152	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALOX15—esophageal cancer	1.46e-06	0.00152	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL2—esophageal cancer	1.45e-06	0.00151	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—WWOX—esophageal cancer	1.44e-06	0.0015	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GHRL—esophageal cancer	1.42e-06	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PFN1—esophageal cancer	1.42e-06	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CSNK1A1—esophageal cancer	1.42e-06	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ANXA1—esophageal cancer	1.4e-06	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GNG7—esophageal cancer	1.39e-06	0.00145	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTO1—esophageal cancer	1.39e-06	0.00145	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TPI1—esophageal cancer	1.39e-06	0.00145	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—NOS2—esophageal cancer	1.39e-06	0.00145	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FKBP1A—esophageal cancer	1.37e-06	0.00143	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—SST—esophageal cancer	1.36e-06	0.00142	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ANXA1—esophageal cancer	1.35e-06	0.00141	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL2—esophageal cancer	1.35e-06	0.00141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—WIF1—esophageal cancer	1.34e-06	0.0014	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—WWOX—esophageal cancer	1.34e-06	0.0014	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALDOB—esophageal cancer	1.33e-06	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GHRL—esophageal cancer	1.33e-06	0.00139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PFN1—esophageal cancer	1.32e-06	0.00138	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL2—esophageal cancer	1.32e-06	0.00137	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—SST—esophageal cancer	1.31e-06	0.00137	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ADH1B—esophageal cancer	1.31e-06	0.00136	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—NOS2—esophageal cancer	1.3e-06	0.00135	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GAPDH—esophageal cancer	1.28e-06	0.00134	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GHRL—esophageal cancer	1.28e-06	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FKBP1A—esophageal cancer	1.28e-06	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ELMO1—esophageal cancer	1.27e-06	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CRABP1—esophageal cancer	1.27e-06	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ANXA1—esophageal cancer	1.25e-06	0.00131	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TYMP—esophageal cancer	1.25e-06	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—CREBBP—esophageal cancer	1.25e-06	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—WIF1—esophageal cancer	1.25e-06	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKAP13—esophageal cancer	1.25e-06	0.0013	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CSNK1A1—esophageal cancer	1.24e-06	0.00129	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ANXA1—esophageal cancer	1.23e-06	0.00128	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL2—esophageal cancer	1.23e-06	0.00128	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—SST—esophageal cancer	1.22e-06	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.22e-06	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP26A1—esophageal cancer	1.22e-06	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GNG7—esophageal cancer	1.21e-06	0.00126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—SST—esophageal cancer	1.19e-06	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ELMO1—esophageal cancer	1.19e-06	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GHRL—esophageal cancer	1.19e-06	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALOX15—esophageal cancer	1.18e-06	0.00123	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	1.17e-06	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—CREBBP—esophageal cancer	1.17e-06	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKAP13—esophageal cancer	1.16e-06	0.00121	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GHRL—esophageal cancer	1.16e-06	0.00121	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PFN1—esophageal cancer	1.16e-06	0.00121	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CSNK1A1—esophageal cancer	1.15e-06	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HIST1H2BM—esophageal cancer	1.15e-06	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	1.14e-06	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ANXA1—esophageal cancer	1.14e-06	0.00119	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	1.14e-06	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PDE4D—esophageal cancer	1.14e-06	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALDH2—esophageal cancer	1.13e-06	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TPI1—esophageal cancer	1.13e-06	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTO1—esophageal cancer	1.13e-06	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—NOS3—esophageal cancer	1.12e-06	0.00116	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—SST—esophageal cancer	1.11e-06	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GNG7—esophageal cancer	1.08e-06	0.00113	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALDOB—esophageal cancer	1.08e-06	0.00113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GHRL—esophageal cancer	1.08e-06	0.00113	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTT1—esophageal cancer	1.08e-06	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PFN1—esophageal cancer	1.08e-06	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIST1H2BM—esophageal cancer	1.07e-06	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP2A6—esophageal cancer	1.07e-06	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PDE4D—esophageal cancer	1.06e-06	0.00111	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—NOS2—esophageal cancer	1.06e-06	0.0011	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—NOS3—esophageal cancer	1.04e-06	0.00109	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GAPDH—esophageal cancer	1.04e-06	0.00109	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ELMO1—esophageal cancer	1.04e-06	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CRABP1—esophageal cancer	1.03e-06	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	1.02e-06	0.00106	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKAP13—esophageal cancer	1.02e-06	0.00106	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—XIAP—esophageal cancer	1.02e-06	0.00106	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNG7—esophageal cancer	1.01e-06	0.00105	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ENO1—esophageal cancer	1.01e-06	0.00105	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS1—esophageal cancer	1.01e-06	0.00105	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PSME2—esophageal cancer	9.96e-07	0.00104	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PSME1—esophageal cancer	9.96e-07	0.00104	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GNG7—esophageal cancer	9.83e-07	0.00102	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ELMO1—esophageal cancer	9.67e-07	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNA1—esophageal cancer	9.6e-07	0.001	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL2—esophageal cancer	9.54e-07	0.000994	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—XIAP—esophageal cancer	9.48e-07	0.000988	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—CREBBP—esophageal cancer	9.47e-07	0.000987	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKAP13—esophageal cancer	9.45e-07	0.000984	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIST1H2BM—esophageal cancer	9.38e-07	0.000978	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDE4D—esophageal cancer	9.3e-07	0.000969	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	9.26e-07	0.000965	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALDH2—esophageal cancer	9.21e-07	0.00096	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNA1—esophageal cancer	8.97e-07	0.000934	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PSME2—esophageal cancer	8.91e-07	0.000929	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PSME1—esophageal cancer	8.91e-07	0.000929	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL2—esophageal cancer	8.91e-07	0.000929	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ANXA1—esophageal cancer	8.87e-07	0.000924	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNG7—esophageal cancer	8.85e-07	0.000921	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTT1—esophageal cancer	8.76e-07	0.000913	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	8.72e-07	0.000908	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP2A6—esophageal cancer	8.66e-07	0.000902	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	8.64e-07	0.0009	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SST—esophageal cancer	8.63e-07	0.000899	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP1B1—esophageal cancer	8.59e-07	0.000895	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—EP300—esophageal cancer	8.51e-07	0.000886	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—NOS3—esophageal cancer	8.48e-07	0.000884	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GHRL—esophageal cancer	8.41e-07	0.000876	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH3—esophageal cancer	8.41e-07	0.000876	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PSME2—esophageal cancer	8.33e-07	0.000868	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PSME1—esophageal cancer	8.33e-07	0.000868	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—XIAP—esophageal cancer	8.29e-07	0.000863	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ANXA1—esophageal cancer	8.29e-07	0.000863	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FBXW7—esophageal cancer	8.27e-07	0.000862	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	8.22e-07	0.000856	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS1—esophageal cancer	8.21e-07	0.000855	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ENO1—esophageal cancer	8.21e-07	0.000855	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PSME1—esophageal cancer	8.09e-07	0.000843	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PSME2—esophageal cancer	8.09e-07	0.000843	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP19A1—esophageal cancer	8.08e-07	0.000842	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SST—esophageal cancer	8.06e-07	0.00084	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—EP300—esophageal cancer	7.94e-07	0.000828	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GHRL—esophageal cancer	7.86e-07	0.000818	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH3—esophageal cancer	7.86e-07	0.000818	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNA1—esophageal cancer	7.84e-07	0.000817	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	7.79e-07	0.000812	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FBXW7—esophageal cancer	7.73e-07	0.000805	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	7.7e-07	0.000802	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH2—esophageal cancer	7.54e-07	0.000786	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—HMOX1—esophageal cancer	7.37e-07	0.000768	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	7.28e-07	0.000759	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	7.28e-07	0.000758	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	7.28e-07	0.000758	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	7.24e-07	0.000755	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	7.24e-07	0.000754	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ABCB1—esophageal cancer	7.08e-07	0.000737	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SST—esophageal cancer	7.05e-07	0.000734	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH2—esophageal cancer	7.05e-07	0.000734	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP1B1—esophageal cancer	6.98e-07	0.000727	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	6.87e-07	0.000716	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	6.87e-07	0.000716	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	6.76e-07	0.000705	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	6.76e-07	0.000705	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	6.76e-07	0.000704	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	6.73e-07	0.000701	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFBR2—esophageal cancer	6.69e-07	0.000697	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP19A1—esophageal cancer	6.56e-07	0.000684	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SST—esophageal cancer	6.55e-07	0.000682	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—EP300—esophageal cancer	6.45e-07	0.000672	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	6.38e-07	0.000665	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	6.38e-07	0.000665	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SMAD4—esophageal cancer	6.33e-07	0.00066	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—PIK3CA—esophageal cancer	6.29e-07	0.000655	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	6.28e-07	0.000654	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFBR2—esophageal cancer	6.25e-07	0.000651	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	6.16e-07	0.000642	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—esophageal cancer	6.09e-07	0.000634	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—esophageal cancer	5.99e-07	0.000624	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SMAD4—esophageal cancer	5.92e-07	0.000616	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—PIK3CA—esophageal cancer	5.88e-07	0.000612	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ABCB1—esophageal cancer	5.75e-07	0.000599	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	5.72e-07	0.000596	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—esophageal cancer	5.69e-07	0.000592	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	5.46e-07	0.000569	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	5.18e-07	0.00054	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	5.17e-07	0.000539	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	5.08e-07	0.000529	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KDR—esophageal cancer	4.96e-07	0.000516	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—esophageal cancer	4.84e-07	0.000504	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	4.81e-07	0.000501	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	4.77e-07	0.000497	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CREBBP—esophageal cancer	4.73e-07	0.000493	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	4.67e-07	0.000486	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—esophageal cancer	4.63e-07	0.000482	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—esophageal cancer	4.62e-07	0.000481	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	4.36e-07	0.000454	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—esophageal cancer	4.23e-07	0.000441	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	4.23e-07	0.000441	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	4.23e-07	0.000441	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	4.16e-07	0.000433	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	4.05e-07	0.000422	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.98e-07	0.000414	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	3.95e-07	0.000412	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	3.93e-07	0.00041	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	3.89e-07	0.000405	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—esophageal cancer	3.87e-07	0.000403	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CREBBP—esophageal cancer	3.84e-07	0.0004	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	3.81e-07	0.000397	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	3.79e-07	0.000395	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	3.76e-07	0.000392	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.71e-07	0.000387	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	3.61e-07	0.000376	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	3.55e-07	0.000369	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	3.54e-07	0.000369	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	3.54e-07	0.000369	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	3.46e-07	0.00036	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—esophageal cancer	3.44e-07	0.000358	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	3.4e-07	0.000354	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	3.37e-07	0.000351	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	3.31e-07	0.000345	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.25e-07	0.000338	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—EP300—esophageal cancer	3.22e-07	0.000336	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	3.21e-07	0.000335	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	3.16e-07	0.000329	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—esophageal cancer	3.15e-07	0.000328	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	3.13e-07	0.000326	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	3.1e-07	0.000322	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	3.03e-07	0.000316	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	3.02e-07	0.000314	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	2.95e-07	0.000307	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	2.93e-07	0.000305	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	2.9e-07	0.000302	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EP300—esophageal cancer	2.88e-07	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	2.88e-07	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	2.83e-07	0.000295	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.74e-07	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EP300—esophageal cancer	2.69e-07	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	2.69e-07	0.00028	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—EP300—esophageal cancer	2.62e-07	0.000273	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	2.56e-07	0.000266	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—esophageal cancer	2.51e-07	0.000262	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	2.47e-07	0.000258	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	2.46e-07	0.000256	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—esophageal cancer	2.38e-07	0.000248	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	2.38e-07	0.000248	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	2.35e-07	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—esophageal cancer	2.35e-07	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	2.3e-07	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	2.3e-07	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2.19e-07	0.000228	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	2.13e-07	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—esophageal cancer	2.06e-07	0.000215	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	2.05e-07	0.000214	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	2.01e-07	0.000209	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.99e-07	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.94e-07	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.93e-07	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.91e-07	0.000199	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.86e-07	0.000194	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.74e-07	0.000181	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.68e-07	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1.62e-07	0.000169	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	1.57e-07	0.000163	CbGpPWpGaD
